In vitro study reveals reduced toxicity biomarkers from liquiritigenin derivatives in GalN/LPS-treated cells, indicating isoliquiritigenin provides superior hepatoprotection.
Liquiritigenin (7,4'-dihydroxyflavanone), isolated from the roots of Glycyrrhiza glabra, was derivatized to liquiritigenin 7, 4'-diacetate, liquiritigenin 4'-acetate, isoliquiritigenin, and liquiritigenin 7, 4'-dibenzoate. All these derivatives were evaluated for in vitro hepatoprotective activity against D-galactosamine-lipopolysaccharide(GalN/LPS) induced toxicity. In-vitro hepatotoxicity was manifested by a significant increase (P < 0.05) in liver toxicity biomarkers (SGPT, SGOT, ALKP, triglyceride, LPO, NO and LDH). The level of biomarkers in the treatment groups was significantly decreased (P < 0.05) when compared with the GalN/LPS group. The results revealed that isoliquiritigenin exhibited better hepatoprotective activity than liquiritigenin and its derivatives.
No takes yet. Share an insight, caveat, or question.
Gaur et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: